If you want to understand why a study takes too long to activate, why an eligible patient never gets approached, or why monitoring actions stay open, look at the handoffs. The work often slows down after one person finishes and before the next person realizes the ball is theirs.
Clinical research has plenty of checklists. What it often lacks is visibility into waiting time. A contract can be “in process” for three weeks. A participant can be “being reviewed” until the treatment window closes. A monitoring action can be “with the PI” without anyone knowing when it will come back.
I have spent years managing studies and teams where the difference between a smooth portfolio and a frustrating one was not whether people worked hard. They did. The difference was whether the handoffs were designed.
Why handoffs matter so much in clinical trial operations
Research sites are cross-functional by design. One study can touch a PI, coordinator, regulatory specialist, budget and contract teams, pharmacy, lab, imaging, scheduling, data management, sponsor/CRO personnel, and institutional reviewers. That means even a good individual workflow can fail at the boundary between functions.
Current industry data supports what site teams feel every day. In WCG's 2025 site survey, study start-up, staffing, recruitment and retention, initiation timelines, sponsor technology, and financial management all appeared among sites' leading challenges. ACRP's startup guidance similarly emphasizes mapping reviewers, approvers, handoffs, and the “whitespace” spent waiting between steps.
Seven clinical trial handoffs I would map first
Feasibility → startup
Feasibility learns things startup desperately needs: special imaging, staffing assumptions, recruitment constraints, pharmacy requirements, competing studies, budget pressure, and internal dependencies. Too often, those details live in a questionnaire and do not become the startup plan.
What to fix: require a short feasibility-to-startup handoff that lists the assumptions behind the “yes,” known constraints, and anything that must be resolved before activation. Our clinical trial site feasibility checklist is designed around exactly that decision.
Contracts/budget → operational team
The people negotiating a budget may understand reimbursement rules and contract language but not always the full labor behind the protocol. The team running the study may later discover uncompensated specimen processing, repeated safety work, screen failures, or intensive data requirements.
What to fix: build an operational review into budget development. Let the people who understand the visit schedule, data burden, pharmacy, laboratory work, and long-term follow-up identify recurring effort before terms are final.
Regulatory approval → activation readiness
IRB approval is a milestone, not proof that the site is ready to enroll. Contracts, training, delegation, pharmacy, system access, supplies, source tools, lab setup, scheduling, and internal green-light requirements may still be open.
What to fix: define activation as a set of explicit green-light conditions. Use a single readiness view instead of allowing each function to track its own version of “almost done.” If activation is consistently slipping, see our start-up and activation readiness service.
Clinic → research team
This is where enrollment can disappear without creating a formal screen failure. A potentially eligible patient is seen in clinic, but the research team learns too late, the treating physician assumes someone else will mention the study, or the patient leaves before the approach can happen.
What to fix: decide exactly how potential participants are flagged, who reviews them, when the research team is notified, and who owns the approach. Measure identification-to-approach, not only consent and enrollment. The GU screening guide goes deeper into this pathway.
Monitor → site owner → PI
A monitoring report arrives. Some items belong to the coordinator, some to regulatory, some require PI review, and one may need sponsor clarification. Without a central action log, findings fragment immediately.
What to fix: assign one accountable owner per finding, define the evidence required for closure, and escalate PI-dependent actions on a predictable cadence. See our guide to clinical trial monitoring follow-up and CAPA closure.
Source/data entry → query resolution
Data problems often begin upstream. If source documentation is inconsistent, if data entry expectations are unclear, or if queries are returned to someone who no longer remembers the visit, query aging becomes a workflow issue rather than a data-team issue.
What to fix: agree on who enters what, expected turnaround, who reviews aging queries, and when repeated query types trigger a source-document or training change. For complex workflows, our research data and study workflow work can help map ownership.
Study-level issue → portfolio leadership
A single study can absorb extra effort for months before leadership sees the pattern. One coordinator is carrying repeated sponsor escalations, another study has overdue monitoring actions, and a third is opening at the same time. Each issue looks manageable alone. Together they create portfolio risk.
What to fix: create a short portfolio review that surfaces activation status, enrollment risk, open quality actions, staffing pressure, and upcoming milestones. Leadership does not need every detail. It needs the exceptions that require a decision.
How to map a handoff without turning it into a six-month process-improvement project
Start with one study or one pain point. For each transition, write down:
- Who finishes the upstream work?
- What exactly tells the next person the work is ready?
- Who owns the next action?
- Where is the status visible?
- How long should the handoff take?
- What happens if the next owner does not act?
Then compare the intended process with a few real cases. The gap between the two usually tells you more than another meeting.
The metric I care about most: aging
Completion rates can hide a slow process. If everything eventually closes, a monthly dashboard may look healthy even while participants wait, startup drifts, and staff chase old tasks.
Aging exposes that problem. How long has this contract been waiting for review? How many days from patient identification to approach? How long are monitoring findings open? How old are unresolved queries? How long from final prerequisite to activation?
Once you can see aging by step, you can stop asking people to “work faster” and start asking why work waits where it waits.
When to redesign the workflow
Not every delay needs a new SOP or new technology. Sometimes a named owner and a weekly review are enough. I would consider a deeper redesign when:
- the same handoff fails across multiple studies;
- work depends on one person remembering to chase it;
- status cannot be seen without asking several people;
- rework is common because upstream information is incomplete;
- the team has added spreadsheets or side channels to compensate for a system that does not fit the work; or
- the delay is affecting participant access, activation, quality, or financial performance.
The takeaway
A clinical trial site workflow is not just the tasks inside each department. It is the movement between them.
If you are trying to improve startup, enrollment, quality, or portfolio performance, map the handoffs before buying a new tool or adding another meeting. The bottleneck is often sitting in plain sight—in the time after one team says “done” and before the next team starts.
Merindale's site performance diagnostic and portfolio operations work are built around finding those constraints in real workflows and leaving the team with a clearer operating cadence.